Skip to content

Author

Kei Motoki

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Body Mass Index-Related Trends in Adverse Events with Enfortumab Vedotin: Analysis of a Pharmacovigilance Database and Medical Records.

Enfortumab vedotin (EV) is an antibody-drug conjugate used to treat advanced urothelial carcinoma. Although effective, it frequently causes adverse events, particularly skin toxicity. Body mass index (BMI) has been suggested as a risk factor for EV toxicity, but evidence from large-scale studies remains limited. This s...

Kei Motoki, Shiori Sato, R. Yamaga et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.